List of Vyxeos drug patents

Vyxeos is owned by Celator Pharms.

Vyxeos contains Cytarabine; Daunorubicin.

Vyxeos has a total of 9 drug patents out of which 0 drug patents have expired.

Vyxeos was authorised for market use on 03 August, 2017.

Vyxeos is available in powder;intravenous dosage forms.

Vyxeos can be used as for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older, method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older, method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older; method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older, method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older.

The generics of Vyxeos are possible to be released after 29 September, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431806 CELATOR PHARMS Liposomal formulations of anthracycline agents and cytidine analogs
Apr, 2025

(2 years from now)

US8518437 CELATOR PHARMS Lipid carrier compositions with enhanced blood stability
Jun, 2026

(3 years from now)

US7850990 CELATOR PHARMS Compositions for delivery of drug combinations
Jan, 2027

(3 years from now)

US9271931 CELATOR PHARMS Compositions for delivery of drug combinations
Jan, 2027

(3 years from now)

US8022279 CELATOR PHARMS Liposomal formulations of anthracycline agents and cytidine analogs
Sep, 2027

(4 years from now)

US8092828 CELATOR PHARMS Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
Apr, 2029

(6 years from now)

US10166184 CELATOR PHARMS Method of lyophilizing liposomes
Oct, 2032

(9 years from now)

US10835492 CELATOR PHARMS Method of lyophilizing liposomes
Oct, 2032

(9 years from now)

US10028912 CELATOR PHARMS Method of lyophilizing liposomes
Sep, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 3, 2024
New Patient Population (NPP) Mar 30, 2024

Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient

Market Authorisation Date: 03 August, 2017

Treatment: For the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older; Method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older; Method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic